Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Lab Autom ; 19(1): 1-18, 2014 Feb.
Article in English | MEDLINE | ID: mdl-23813915

ABSTRACT

Effective intracellular delivery is a significant impediment to research and therapeutic applications at all processing scales. Physical delivery methods have long demonstrated the ability to deliver cargo molecules directly to the cytoplasm or nucleus, and the mechanisms underlying the most common approaches (microinjection, electroporation, and sonoporation) have been extensively investigated. In this review, we discuss established approaches, as well as emerging techniques (magnetofection, optoinjection, and combined modalities). In addition to operating principles and implementation strategies, we address applicability and limitations of various in vitro, ex vivo, and in vivo platforms. Importantly, we perform critical assessments regarding (1) treatment efficacy with diverse cell types and delivered cargo molecules, (2) suitability to different processing scales (from single cell to large populations), (3) suitability for automation/integration with existing workflows, and (4) multiplexing potential and flexibility/adaptability to enable rapid changeover between treatments of varied cell types. Existing techniques typically fall short in one or more of these criteria; however, introduction of micro-/nanotechnology concepts, as well as synergistic coupling of complementary method(s), can improve performance and applicability of a particular approach, overcoming barriers to practical implementation. For this reason, we emphasize these strategies in examining recent advances in development of delivery systems.


Subject(s)
Drug Delivery Systems , Intracellular Space , Nanotechnology/methods , Animals , Humans
2.
Biotechnol Bioeng ; 109(4): 1074-82, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22094821

ABSTRACT

One of the most promising cell-based therapies for combating insulin-dependent diabetes entails the use of genetically engineered non-ß cells that secrete insulin in response to physiologic stimuli. A normal pancreatic ß cell secretes insulin in a biphasic manner in response to glucose. The first phase is characterized by a transient stimulation of insulin to rapidly lower the blood glucose levels, which is followed by a second phase of insulin secretion to sustain the lowered blood glucose levels over a longer period of time. Previous studies have demonstrated hepatic and enteroendocrine cells to be appropriate hosts for recombinant insulin expression. Due to different insulin secretion kinetics from these cells, we hypothesized that a combination of the two cell types would mimic the biphasic insulin secretion of normal ß cells with higher fidelity than either cell type alone. In this study, insulin secretion experiments were conducted with two hepatic cell lines (HepG2 and H4IIE) transduced with 1 of 3 adenoviruses expressing the insulin transgene and with a stably transfected recombinant intestinal cell line (GLUTag-INS). Insulin secretion was stimulated by exposing the cells to glucose only (hepatic cells), meat hydrolysate only (GLUTag-INS), or to a cocktail of the two secretagogues. It was found experimentally that the recombinant hepatic cells secreted insulin in a more sustained manner, whereas the recombinant intestinal cell line exhibited rapid insulin secretion kinetics upon stimulation. The insulin secretion profiles were computationally combined at different cell ratios to arrive at the combinatorial kinetics. Results indicate that combinations of these two cell types allow for tuning the first and second phase of insulin secretion better than either cell type alone. This work provides the basic framework in understanding the secretion kinetics of the combined system and advances it towards preclinical studies.


Subject(s)
Enteroendocrine Cells/metabolism , Hepatocytes/metabolism , Insulin/metabolism , Adenoviridae/genetics , Animals , Cell Line/drug effects , Cell Line/metabolism , Coculture Techniques , Drug Interactions , Enteroendocrine Cells/drug effects , Genetic Vectors/genetics , Glucose/pharmacology , Hep G2 Cells/drug effects , Hep G2 Cells/metabolism , Hepatocytes/drug effects , Humans , Insulin/genetics , Insulin Secretion , Liver Neoplasms, Experimental/pathology , Mice , Proinsulin/genetics , Protein Hydrolysates/pharmacology , Rats , Recombinant Fusion Proteins/metabolism , Secretory Rate/drug effects , Transduction, Genetic
3.
Biotechnol Prog ; 25(4): 973-9, 2009.
Article in English | MEDLINE | ID: mdl-19399903

ABSTRACT

Paracoccus pantotrophus expresses two nitrate reductases-membrane bound nitrate reductase (Nar) and periplasmic nitrate reductase (Nap). In growth experiments with two denitrifying species (Paracoccus pantotrophus and Alcaligenes eutrophus) that have both Nap and Nar and two species (Pseudomonas denitrificans and Pseudomonas fluorescens) with Nar only, it was found that diauxic lag is shorter for bacteria that express Nap. In P. pantotrophus, napEDABC encodes the periplasmic nitrate reductase. To analyze the effect of Nap on diauxic lag, the nap operon was deleted from P. pantotrophus. The growth experiments with nap(-) mutant resulted in increased diauxic lag when switched from aerobic to anoxic respiration, suggesting Nap is responsible for shorter lags and helps in adaptation to anoxic metabolism after transition from aerobic conditions.


Subject(s)
Bacterial Proteins/metabolism , Nitrate Reductase/metabolism , Paracoccus pantotrophus/enzymology , Paracoccus pantotrophus/growth & development , Periplasmic Proteins/metabolism , Aerobiosis , Anaerobiosis , Bacterial Proteins/genetics , Nitrate Reductase/genetics , Paracoccus pantotrophus/genetics , Periplasmic Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...